AbbVie announced that it has completed the acquisition of Allergan following regulatory approval from all government agencies required by the transaction agreement and approval by the Irish High Court.
AbbVie said the acquisition will significantly expand and diversify the company’s revenue base and complements existing leadership positions in areas such as immunology (Humira, Skyrizi and Rinvoq), hematologic oncology (Imbruvica and Venclexta), neuroscience (Botox, Vraylar, and Ubrelvy) and its global aesthetics business (Botox and Juvederm).
"We are pleased to reach this important milestone for the company, its employees, shareholders and the patients we serve," AbbVie Chairman and CEO Richard A. Gonzalez said. "Our new Allergan colleagues should be commended for all their efforts, along with those of our own employees, to achieve this turning point for our company.”
The new AbbVie will be a well-diversified leader in many important therapeutic categories, with both on-market and pipeline assets, and the company’s financial strength will allow it to continue to invest in innovative science and continue to serve unmet medical needs of patients that rely upon the company, he added.
<© Korea Biomedical Review, All rights reserved.>